Attached files

file filename
EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2016093010qex321.htm
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2016093010qex312.htm
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2016093010qex311.htm
10-Q - 10-Q - PDL BIOPHARMA, INC.pdli-2016093010qdoc.htm


Exhibit 12.1

PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)



 
 
 
 
 
 
 
 
 
 
 
 
For the Nine Months Ended September 30, 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2011
 
2012
 
2013
 
2014
 
2015
 
Earnings:
 
 
 
 
 
 
 
 
 
 
 
 
Income before income taxes
 
$
307,428

 
$
327,133

 
$
401,876

 
$
501,272

 
$
530,138

 
$
123,950

Add: fixed charges
 
36,153

 
29,097

 
24,931

 
39,274

 
27,123

 
13,571

Earnings
 
$
343,581

 
$
356,230

 
$
426,807

 
$
540,546

 
$
557,261

 
$
137,521

Fixed Charges:
 
 
 
 
 
 
 
 
 
 
 
 
Interest expense1
 
$
36,102

 
$
29,036

 
$
24,871

 
$
39,211

 
$
27,059

 
$
13,524

Estimated interest portion of rent expense2
 
51

 
61

 
60

 
63

 
64

 
47

Fixed charges
 
36,153

 
$
29,097

 
$
24,931

 
$
39,274

 
$
27,123

 
$
13,571

Ratio of earnings to fixed charges
 
9.50

 
12.24

 
17.12

 
13.76

 
20.55

 
10.13

_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.